Associated Papers
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.
Tabata J et al.
Cancer Research, 2022
Emerging glioneuronal and neuronal tumors: case-based review.
Lim SD et al.
Brain Tumor Pathology, 2022
Diffuse leptomeningeal glioneuronal tumour (DLGNT) in children: the emerging role of genomic analysis.
Manoharan N et al.
Acta Neuropathologica Communications, 2021
REToma: a cancer subtype with a shared driver oncogene.
Kohno T et al.
Carcinogenesis, 2020
The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma.
Qi XP et al.
Journal of Biosciences, 2014
The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A.
Schulte KM et al.
The Journal of Clinical Endocrinology and Metabolism, 2010
When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
Calva D et al.
Annals of Surgical Oncology, 2009
Structure and chemical inhibition of the RET tyrosine kinase domain.
Knowles PP et al.
The Journal of Biological Chemistry, 2006
Minireview: RET: normal and abnormal functions.
Santoro M et al.
Endocrinology, 2004
Dysfunction of the RET receptor in human cancer.
Santoro M et al.
Cellular and Molecular Life Sciences : Cmls, 2004
Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
Iwashita T et al.
Oncogene, 1999
Select a paper to view details